Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Effect of interferon-alpha therapy in a patient with common variable immunodeficiency and chronic Epstein-Barr virus infection.

Toraldo R, D'Avanzo M, Tolone C, Canino G, Iafusco F, Notarangelo LD, Ugazio A, Cirillo C.

Pediatr Hematol Oncol. 1995 Sep-Oct;12(5):489-93.

PMID:
8519635
2.

Therapeutic approaches for severe Epstein-Barr virus infection.

Okano M.

Pediatr Hematol Oncol. 1997 Mar-Apr;14(2):109-19. Review.

PMID:
9089739
3.

Epstein-Barr virus-related primary cutaneous amyloidosis. Successful treatment with acyclovir and interferon-alpha.

Drago F, Ranieri E, Pastorino A, Casazza S, Crovato F, Rebora A.

Br J Dermatol. 1996 Jan;134(1):170-4.

PMID:
8745909
5.

Characterization of Epstein-Barr virus-infected cells in benign lymphadenopathy of patients seropositive for human immunodeficiency virus.

Brousset P, Schlaifer D, Roda D, Massip P, Marchou B, Delsol G.

Hum Pathol. 1996 Mar;27(3):263-8.

PMID:
8600041
6.

Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx.

Alfieri C, Tanner J, Carpentier L, PerpĂȘte C, Savoie A, Paradis K, Delage G, Joncas J.

Blood. 1996 Jan 15;87(2):812-7.

7.

Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease.

Sakai Y, Ohga S, Tonegawa Y, Takada H, Nakao F, Nakayama H, Aoki T, Yamamori S, Hara T.

J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):342-6.

PMID:
9703010
8.

A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function.

Lerner AM, Beqaj SH, Deeter RG, Dworkin HJ, Zervos M, Chang CH, Fitzgerald JT, Goldstein J, O'Neill W.

Drugs Today (Barc). 2002 Aug;38(8):549-61. Review.

PMID:
12582420
9.

Tumor specific Epstein-Barr virus infection is not associated with leiomyosarcoma in human immunodeficiency virus negative individuals.

Hill MA, Araya JC, Eckert MW, Gillespie AT, Hunt JD, Levine EA.

Cancer. 1997 Jul 15;80(2):204-10.

PMID:
9217031
10.

Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.

Faro A.

Springer Semin Immunopathol. 1998;20(3-4):425-36. Review.

PMID:
9870255
11.

Treatment of life-threatening Epstein-Barr virus infection with acyclovir.

Sullivan JL, Byron KS, Brewster FE, Sakamoto K, Shaw JE, Pagano JS.

Am J Med. 1982 Jul 20;73(1A):262-6.

PMID:
6285718
12.

Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.

Toomey NL, Deyev VV, Wood C, Boise LH, Scott D, Liu LH, Cabral L, Podack ER, Barber GN, Harrington WJ Jr.

Oncogene. 2001 Oct 25;20(48):7029-40.

13.

[Epstein-Barr virus-associated hemophagocytic syndrome during mid-term pregnancy successfully treated with combined methylprednisolone and intravenous immunoglobulin].

Mihara H, Kato Y, Tokura Y, Hattori Y, Sato A, Kobayashi H, Imamura A, Daimaru O, Miwa H, Nitta M.

Rinsho Ketsueki. 1999 Dec;40(12):1258-64. Review. Japanese.

PMID:
10658479
14.

Periodic illness associated with Epstein-Barr virus infection.

Lekstrom-Himes JA, Dale JK, Kingma DW, Diaz PS, Jaffe ES, Straus SE.

Clin Infect Dis. 1996 Jan;22(1):22-7.

PMID:
8824960
17.

[Adoptive transfer of Epstein-Barr virus-specific T-lymphocytes in chronic active Epstein-Barr infection].

Babel N, Hammer MH, Reinke P.

Dtsch Med Wochenschr. 2003 Mar 14;128(11):548-50. German.

PMID:
12635027
18.

Treatment of EBV driven lymphoproliferation with erythrophagocytosis: 12 year follow up.

Bethune CA, Gompels MM, Taylor C, Angus B, Spickett GP.

J Clin Pathol. 2001 Apr;54(4):328-31.

20.

Characterization and sensitivity to interleukin 2 and interferon alpha of leukemic cells from a patient with large granular lymphocytic leukemia associated with chronic active Epstein-Barr virus infection.

Toba K, Koike T, Takahashi M, Kishi K, Hashimoto S, Takahashi H, Uesugi Y, Ishikawa T, Aoki S, Maeo S, Naito M, Aizawa Y, Shibata A.

Leuk Res. 1997 Oct;21(10):941-50.

PMID:
9403005

Supplemental Content

Support Center